

1 **Comprehensive Genetic Profiling of Sensorineural Hearing Loss Using an**
2 **Integrative Diagnostic Approach**

3 Sang-Yeon Lee^{1,2,3,8}, Seungbok Lee^{2,4,8}, Seongyeol Park^{5,8}, Sung Ho Jung¹, Yejin
4 Yun¹, Won Hoon Choi¹, Ju Hyuen Cha¹, Hongseok Yun², Sangmoon Lee⁵, Myung-
5 Whan Suh¹, Moo Kyun Park¹, Jae-Jin Song⁶, Byung Yoon Choi⁶, Jun Ho Lee¹, Young
6 Seok Ju^{5,7}, June-Young Koh^{5,*}, Jong-Hee Chae^{2,4,*}

7 ¹ Department of Otorhinolaryngology, Seoul National University College of Medicine,
8 Seoul National University Hospital, Seoul, South Korea

9 ² Department of Genomic Medicine, Seoul National University Hospital, Seoul, South
10 Korea

11 ³ Sensory Organ Research Institute, Seoul National University Medical Research
12 Center

13 ⁴ Department of Pediatrics, Seoul National University College of Medicine, Seoul
14 National University Children's Hospital, Seoul, South Korea

15 ⁵ Inocras Inc., San Diego, California, United States

16 ⁶ Department of Otorhinolaryngology, Seoul National University College of Medicine,
17 Seoul National University Bundang Hospital, Seongnam, South Korea

18 ⁷ Graduate School of Medical Science and Engineering, Korea Advanced Institute of
19 Science and Technology, Daejeon, South Korea

20 ⁸ These authors contributed equally to this work.

21

22 *** Corresponding author**

23 **June-Young Koh**

24 Inocras, Inc., 6330 Nancy Ridge Drive Suite 106, San Diego, CA 92121, United

25 States

26 Tel : +1-858-665-2120

27 E-mail: jy.koh@inocras.com

28

29 **Jong-Hee Chae**

30 Division of Pediatric Neurology, Department of Pediatrics,

31 Pediatric Clinical Neuroscience Center, Seoul National University Children's Hospital,

32 Seoul National University College of Medicine

33 101 Daehakro Jongno-gu, Seoul, South Korea 03080

34 Tel : +82-2-2072-3622; Fax : +82-2-7433455

35 E-mail: chaeped1@snu.ac.kr

36

37 **Total number of words**

38 Abstract (188), Main Text (3,756)

39 **Abstract**

40 Despite the advent of Next-Generation Sequencing (NGS), genetic diagnosis of
41 genetic disorders remains challenging, with diagnostic rates plateauing at
42 approximately 50%. We investigated sensorineural hearing loss (SNHL), a prevalent
43 sensory disorder with substantial genetic heterogeneity, through a comprehensive
44 genomic analysis of a homogeneous disease cohort. Leveraging 394 families (750
45 individuals), we implemented a systematic multi-tiered genomic approach
46 encompassing single-gene analysis to whole-genome sequencing (WGS), integrated
47 with functional assays and bioinformatic analysis. Our methodological framework
48 revealed a cumulative diagnostic yield of 55.6% (219 families), with automated WGS
49 bioinformatics pipeline uncovering an additional 20 families harboring pathogenic
50 variants, predominantly structural variants. Notably, comparative genomic analysis
51 unveiled a higher frequency of single pathogenic alleles in recessive genes within
52 our SNHL cohort relative to control populations. Subsequent deep intronic region
53 interrogation identified three pathogenic variants on the opposite allele,
54 substantiating the diagnostic utility of comprehensive genomic profiling. Through this
55 approach, we delineated a genome-phenome landscape of SNHL, elucidating
56 molecular signatures and establishing genotype-phenotype correlations at the inner
57 ear functional level. This study underscores the transformative potential of WGS as a
58 robust molecular diagnostic modality, advancing precision medicine paradigms in
59 genetic disease research.

60 **Keywords:** Sensorineural hearing loss; Whole-genome sequencing; Stepwise
61 genomic approach; Genotype-phenotype correlations

62 **Introduction**

63 Hearing is the primary sense used for human communication and an
64 important component in the development of language and music. Thus, hearing
65 impairment, the most common sensory deficit in humans, is a major public health
66 problem, affecting approximately 466 million people worldwide (World Health
67 Organization, [https://who.int/news-room/fact-sheets/detail/deafness-and-hearing-](https://who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss)
68 [loss](https://who.int/news-room/fact-sheets/detail/deafness-and-hearing-loss)). Sensorineural hearing loss (SNHL)—i.e., defective sound signaling in the
69 auditory sensory system—can be caused by multiple etiologies, including genetic
70 causes, congenital infections, trauma, ototoxic medications, and autoimmune
71 disorders¹. Since the 2010s, advances in high-throughput next-generation
72 sequencing (NGS) technologies have facilitated extensive elucidation of the genetic
73 backgrounds of SNHL, with a focus on monogenic forms of deafness. Notably,
74 mouse genetics studies have helped reveal the physiological basis of SNHL in
75 humans and the associated molecular functions².

76 Despite growing recognition of the significance of genetic diagnosis of
77 SNHL, it remains challenging to identify a genetic diagnosis in SNHL with substantial
78 genetic heterogeneity^{3,4}. NGS is increasingly favored for genetic diagnosis due to its
79 capacity for simultaneous large-scale genetic loci screening, and methods like
80 targeted panel sequencing (TPS) and whole-exome sequencing (WES) were widely
81 used in real-world practice⁵⁻⁷. In the literature, targeted sequencing for SNHL has
82 achieved diagnostic yields of between 12.7% and 64.3%⁸⁻¹¹. However, even after
83 exome sequencing, approximately 50% of cases remain genetically elusive.

84 As the cost of sequencing dramatically declines¹², the clinical application of
85 whole-genome sequencing (WGS) becomes more feasible, which has a higher
86 capability to detect a more diverse spectrum of genomic variants that had not

87 previously been captured by exome sequencing or other targeted approaches^{13,14}.
88 Recent studies have shown the clinical utility of WGS for the genetic diagnosis of
89 several disorders and effectively shortening their diagnostic odyssey, increasingly
90 considered as a first-line genetic test¹⁵⁻¹⁹. However, WGS is not yet widely applied in
91 routine clinical settings for diagnosing patients with rare diseases, including SNHL,
92 due to several limitations, such as the difficulties of rapid bioinformatic analysis and
93 accurate clinical interpretation. Additionally, although whole genomes are sequenced,
94 the analysis is often limited to in silico gene panels or the coding regions of the
95 genome²⁰.

96 In the present study, we comprehensively explored the genetic landscape of
97 394 prospective SNHL families. Using a stepwise approach from single target gene
98 analysis to WGS, we evaluated the additional diagnostic value of WGS. We
99 implemented an automated WGS bioinformatics pipeline, integrating *in-house*
100 algorithms with manual curation by both otologists and medical geneticists. This
101 approach allowed comprehensive analysis of all variant types, and improved the
102 diagnostic yield for previously undiagnosed patients. Further analysis of deep
103 intronic regions identified novel pathogenic variants. These findings refined the
104 genotype-phenotype landscape of SNHL, revealing the gene signatures based on
105 phenotypes and identifying genotype-phenotype correlations at the level of inner ear
106 molecular functions. Our results demonstrate the clinical utility of an integrated
107 molecular diagnostic approach, including WGS, in real-world SNHL practice, paving
108 the way toward precision medicine.

109

110 **Results**

111 ***A stepwise approach of genetic testing for patients with SNHL***

112 We conducted stepwise approach of genetic testing, sanger sequencing,
113 TPS, WES, mitochondrial DNA (mtDNA) sequencing, multiplex ligation-dependent
114 probe amplification (MLPA), and WGS, to prospectively recruited SNHL cohort (*n* of
115 probands = 394; *n* of participants including probands and their family members = 750;
116 **Supplementary Table 1**), including non-syndrome hearing loss (ns-SNHL; *n* = 341,
117 86.5%), and syndromic hearing loss (s-SNHL; *n* = 53, 13.5%). Genetic testing was
118 structured into five sequential steps (**Fig. 1 and Supplementary Fig. 1a**). In Step 1,
119 we screened 22 variants from 10 classical deafness genes (*GJB2*, *SLC26A4*,
120 *TMPRSS3*, *CDH23*, *OTOF*, *TMC1*, *ATP1A3*, *MPZL2*, *COCH*, and 12S rRNA). Among
121 cohort, ns-SNHL patients (*n* = 341) were initially subjected to Step 1 and the ns-
122 SNHL patients who remained undiagnosed after Step 1 (*n* = 295), and s-SNHL
123 patients (*n* = 53) were then subjected to the next steps (Steps 2-1 and 2-2). In Step
124 2-1, 99 and 249 patients with SNHL were subjected to TPS (including 246 genes)
125 and WES, respectively. After that, undiagnosed patients with suggestive clinical
126 features, including symmetric mild-to-moderate SNHL (*n* = 51)²¹, apparent branchio-
127 oto-renal/branchio-otic (BOR/BO) syndrome (*n* = 2)²², radiological evidence of
128 enlarged vestibular aqueduct (EVA) (*n* = 1), and suspicious mitochondria disorders
129 (*n* = 11) were subjected to Step 2-2, including MLPA methods (*n* = 54) or mtDNA
130 panel sequencing (*n* = 11). In Step 3-1, among patients who remained undiagnosed,
131 all s-SNHL patients and a representative subset of ns-SNHL patients were selected
132 for WGS using a well-thought-out sample size estimation with a stratified sampling
133 approach (**Supplementary Fig. 1b**). For the remaining undiagnosed patients (*n* =
134 100), deep intronic regions of SNHL-related genes were screened to identify

135 additional pathogenic variants in Step 3-2. After stepwise genetic testing, patients
136 with suspected pathogenic genetic causes underwent subsequent bioinformatic
137 analyses and curation. Multidisciplinary molecular board meetings, comprising both
138 clinicians and genome scientists, were then conducted to confirm genetic diagnosis.

139

140 ***Incremental improvement in diagnostic yield through stepwise genetic testing***
141 ***for SNHL***

142 Through comprehensive genetic testing, we incrementally improved the
143 diagnostic yield in the cohort, identifying disease-causing variants in 219 families
144 (55.6%; **Fig. 2a**). Following the stepwise approach, in Step 1, we identified causal
145 variants in 46 out of 341 patients (diagnostic yield for Step 1: 13.5%; cumulative yield:
146 11.7%). In Step 2-1, causal variants were found in 124 out of 348 patients
147 (diagnostic yield for Step 2-1: 35.6%; cumulative yield: 43.1%), while Step 2-2
148 revealed causal variants in 26 out of 65 patients (diagnostic yield for Step 2-2: 40%;
149 cumulative yield: 49.7%). WGS was performed on 120 patients, identifying causal
150 variants in additional 23 probands (20 in Step 3-1 and 3 in Step 3-2; diagnostic yield
151 for Step 3: 19.2%; cumulative yield: 55.6%). Details of individual patients, including
152 the performed tests, diagnostic outcomes, and identified variants, are summarized in

153 **Supplementary Table 2.**

154 Multivariate analysis revealed that the rate of genetic diagnosis was higher
155 among patients with early identification of SNHL (adjusted odds ratio [OR], 1.32; 95%
156 confidence interval [CI], 1.11–1.57) and those with a family history (adjusted OR,
157 1.55; 95% CI, 1.31–1.82; **Fig. 2b and Supplementary Table 3**). Similarly, patients
158 with syndromic features were more likely to have identified genetic variants (adjusted
159 OR, 1.44; 95% CI, 1.17–1.70). In contrast, a lower rate of genetic diagnosis was

160 observed in patients with adult-onset SNHL (adjusted OR, 0.50; 95% CI, 0.35–0.68),
161 asymmetric hearing loss (adjusted OR, 0.38; 95% CI, 0.18–0.64), and interaural
162 asymmetry (adjusted OR, 0.43; 95% CI, 0.23–0.68). Additionally, in the context of
163 WGS, several features were associated with a higher likelihood of achieving a
164 genetic diagnosis (**Fig. 2c and Supplementary Table 4**). The multivariate analyses
165 suggested that genetic diagnosis was significantly related to the presence of
166 syndromic features (adjusted OR, 2.51; 95% CI, 1.15–5.04) and early identification
167 through a failed newborn hearing screening (NHS) (adjusted OR, 2.35; 95% CI,
168 1.13–4.97). In addition, the diagnostic yield significantly varied depending on the
169 WGS approach. Trio-based WGS had a higher likelihood of identifying causal
170 variants (adjusted OR, 3.71; 95% CI, 1.67–9.68), whereas singleton WGS was less
171 effective (adjusted OR, 0.32; 95% CI, 0.12–0.71).

172 Further, we conducted the correlation analysis between the frequencies of
173 causative variants among our cohort and population allele frequencies of the variants
174 from public databases, such as the gnomAD²³ and KOVA²⁴ (Korean Variant Archive:
175 Korean population database; **Fig. 2d**). We observed the strongest association with
176 East Asians compared to other ethnicity groups within gnomAD, and a notably higher
177 association with KOVA, suggesting that patient ethnicity should be considered in
178 variant discovery. We discovered three outlier variants (*SLC12A3* p.Thr180Lys,
179 *ESRRB* p.Arg382Cys, and *GJB2* p.Val37Ile) when comparing the variant frequencies
180 with allele frequencies in KOVA (**Fig. 2e**). These variants have higher frequencies in
181 the Korean population than in diagnosed patients, suggesting either their low
182 penetrance features or the potential for functional pathogenicity despite its
183 particularly higher allele frequencies²⁵.

184 In conclusion, from Step 1 to Step 3-2, we identified the genetic causes of

185 SNHL in 219 out of 394 probands (55.6%), with 23 diagnoses made through WGS.
186 Among the identified variants, deep intronic variants ($n = 3$) and structural variants
187 (SVs) ($n = 11$) were predominantly detected through WGS, and 13 variants of
188 uncertain significance (VUS) required functional assays to validate their
189 pathogenicity (**Fig. 2f**).

190

191 ***Comprehensive characterization of causative variants in SNHL***

192 Using the genetic findings obtained through comprehensive stepwise
193 genetic tests, we illustrated a mutational landscape of SNHL. Collectively, 63 genes
194 were identified as disease-causing within 219 genetically diagnosed families (**Fig. 3a**
195 **and Supplementary Fig. 2a**). *GJB2* was the most frequently affected gene (10.5%,
196 23/219), followed by five genes (*SLC26A4*, *STRC*, *USH2A*, *CDH23*, and *MPZL2*)
197 that were found in at least ten unrelated families (collectively >40% of all diagnosed
198 cases). Conversely, 29 SNHL-associated genes were detected from only one family
199 (collectively 13.2%; 29/219; **Supplementary Fig. 2a**), suggesting that many more
200 rare genes can cause SNHL. The inheritance patterns of the 63 genes included
201 autosomal recessive (26/63 genes; affecting 132 families; found double hits,
202 including homozygote and compound heterozygote variants), autosomal dominant
203 (33/63 genes; affecting 73 families; found single hit), X-linked (4/63 genes; affecting
204 6 families), and mitochondrial (3/63 genes; affecting 8 families) (**Fig. 3a**). Within our
205 cohort, three identified genes—*TECTA*, *COL4A3*, and *WFS1*—exhibited both
206 autosomal recessive and autosomal dominant inheritance traits. Moreover, one
207 patient exhibited dual genetic etiologies, inherited from their parents, harboring
208 compound heterozygous variants (c.299del:p.His100LeufsTer12 and
209 c.235del:p.Leu79CysfsTer3) in *GJB2* and a heterozygous variant

210 (c.113G>A;p.Gly38Asp) in *COCH*.

211 **Fig. 3b** and **Supplementary Fig. 2b** display the mutational landscapes of
212 the 352 causative variants, including the variant type. Among the 352 identified
213 variants, we found missense variants (157, 44.6%), nonsense variants (51, 14.5%),
214 frameshift variants (63, 17.9%), and inframe variants (10, 2.8%) within the exome
215 region. Additionally, splicing variants (27, 7.7%), SVs (36, 10.2%), and mitochondrial
216 variants (8, 2.3%) were identified. Interestingly, we observed differences in the
217 distribution of variant types across genes. In particular, consistent with previous
218 reports, SVs accounted for (20/30, 66.7%) of the total variants in the *STRC* gene.

219 Among the 352 causative variants (190 when the same variants were
220 collapsed), 83 variants were novel (**Fig. 3c**). All of the 352 variants were either
221 pathogenic (P) or likely pathogenic (LP) according to the American College of
222 Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology
223 (AMP) guidelines (**Supplementary Table 5**)²⁶. A variety of functional studies—
224 ranging from molecular modeling to minigene splicing assay—were performed to test
225 16 highly suggestive variants (**Supplementary Table 6**), leading to the
226 reclassification of 13 variants from “uncertain significance” to “likely pathogenic”. An
227 analysis of the variant type distribution among the 83 novel variants revealed that
228 SVs, detected mostly through WGS, accounted for a much larger proportion (12.0%)
229 compared to previously reported variants (2.8%) (**Fig. 3d**). In addition, we observed
230 an increasing trend in the proportion of patients with novel variants as the steps
231 progressed from Step 1 to Step 3-2 (**Fig. 3e**).

232 Novel SVs identified from WGS include exonic deletions on *SPATA5* and
233 *CLCNKA-CLCNKB* (**Figs. 3f and 3g**). In one patient (SNUH 799), WGS identified a
234 small SV (c.2227-3015_2354+1415del) exclusively involving exon 15 of *SPATA5* (**Fig.**

235 **3f)**, along with an *in trans* short frameshift deletion in exon 16 (c.2679_2680del).
236 Notably, consistent with a previous case report²⁷, this patient exhibited systemic
237 clinical manifestations, including bilateral moderately severe SNHL, intractable
238 epilepsy with diffuse brain atrophy, and global developmental delay (**Supplementary**
239 **Fig. 3a**). Next, we investigated the molecular consequences of the small SV (c.2227-
240 3015_2354+1415del) on *SPATA5*-dependent bioenergetics using Seahorse assays
241 (**Supplementary Fig. 3b**). The oxygen consumption rate (OCR) showed reduced
242 respiratory function in patient fibroblasts, with significant decreases observed in
243 basal respiration ($P < 0.001$), maximal respiration ($P < 0.001$), and ATP production (P
244 < 0.001) compared to control mother fibroblasts (**Supplementary Fig. 3c**). These
245 findings suggest that the small deletion in *SPATA5* (c.2227-3015_2354+1415del)
246 contributes to impaired mitochondrial function leading to SNHL.

247

248 ***Advanced WGS approach revealed additional deep intronic variants***

249 We sought to analyze the variant status of undiagnosed SNHL patients,
250 even after the automated WGS pipeline (Step 3-1 in **Fig.1**) had been performed.
251 Specifically, we examined the frequency of carriers for autosomal recessive SNHL-
252 related genes (**Supplementary Fig. 4a**) in these undiagnosed patients and
253 compared it to the carrier status in control cohorts (HC1: patients with hepatocellular
254 carcinoma, n = 553, HC2: patients with breast cancer, n = 571; **Fig. 4a**). Throughout
255 the analysis, we focused on identifying candidate pathogenic variants in accordance
256 with ACMG guidelines (P/LP variants) and rare variants (minor allele frequency; MAF
257 $< 1\%$) predicted to have a high impact. These included transcript ablation, splice
258 variants, start lost, stop gained/lost, frameshift variants, transcript amplification,
259 feature elongation/truncation, and exon-disrupting SVs or transposable elements

260 (TEs). Subsequently, for SNHL patients with a pathogenic variant on a single allele
261 after Step 3-1, we concentrated on identifying additional pathogenic variants on the
262 opposite allele in Step 3-2. Specifically, *in silico* splicing variant predictions were
263 performed using SpliceAI²⁸ on intronic variants (MAF < 1%) identified in SNHL
264 carriers. This approach aimed to detect potential splice-affecting variants that may
265 have been overlooked in previous analyses.

266 The analysis revealed that the carrier rate for pathogenic variants in SNHL-
267 related genes was significantly higher in the undiagnosed SNHL patient group
268 compared to the two control cohorts (**Fig. 4b**). Additionally, an evaluation of the MAF
269 of the identified candidate pathogenic variants showed that variants found in the
270 undiagnosed SNHL group were rarer than those in the control group (**Fig. 4c**).
271 Subsequent screening for deep intronic variants in undiagnosed SNHL patients
272 identified three *in trans* variants with SpliceAI prediction scores greater than 0.2.
273 These included deep intronic variants in *USH2A* (c.7120+1475A>G, c.14134-
274 3169A>G, and c.4628-26037A>G), each found in different patients (SNUH 485,
275 SNUH 503, and SNUH 513, respectively; **Fig. 4d and Supplementary Fig. 4b-c**). To
276 evaluate their pathogenicity, minigene assays were designed with specific splice
277 donor (SD) and splice acceptor (SA) sites. The assays revealed that these variants
278 induce aberrant splicing that leads to the inclusion of pseudoexons of varying sizes:
279 267 bp for c.7120+1475A>G, 50 bp for c.14134-3169A>G, and 96 bp for c.4628-
280 26037A>G (**Fig. 4e-f**). The resulting aberrant transcripts are predicted to contain
281 premature stop codons, leading to truncated, non-functional usherin protein (**Fig. 4g**).
282 Combined with first hits of the coding variant in this *USH2A* gene (c.10712C>T,
283 c.14835del, and coding deletion, respectively), these alleles of *USH2A* were
284 inactivated in these patients.

285

286 ***Genotype-phenotype correlations through molecular function-based gene***
287 ***clustering***

288 Based on the genetic diagnoses identified through comprehensive genetic
289 analysis, we investigate the relationship between the affected genes and clinical
290 manifestations. We found that causal genes of SNHL were closely linked to specific
291 clinical manifestations, with 22 genes contributing to clinical manifestations in ≥ 3
292 families (**Supplementary Fig. 5a**). The genotype-phenotype map revealed a list of
293 SNHL genes that represent the major attributes of SNHL phenotypes, with over 50%
294 of affected patients harboring variants in the same gene (**Supplementary Fig. 5b**).
295 Although variants within the same causative gene can manifest allelic and clinical
296 heterogeneity^{29,30}, information about signature genes associated with distinct clinical
297 phenotypes may aid in conducting in-depth genetic analyses within the highly
298 heterogeneous genetic landscape of SNHL.

299 Based on these genotype-phenotype correlation, we further analyzed the
300 phenotypic heterogeneity of SNHL according to causal genes considering the
301 functions of the genes in the inner ear. The 63 SNHL-related genes were classified
302 into eight categories based on inner ear molecular functions (**Fig. 5a and**
303 **Supplementary Fig. 5c**)³¹: (1) hair bundle development and function; (2) synaptic
304 transmission; (3) hair cell adhesion and maintenance; (4) cochlear ion homeostasis;
305 (5) transmembrane and extracellular matrix; (6) oxidative stress, autoinflammation,
306 and mitochondrial defect; and (7) transcriptional regulation. To evaluate the
307 relationships between genes across categories, we compared gene expression
308 patterns using publicly available transcriptome data from human inner ear organoids
309 and human cochlear and vestibular organs³². Comparative analysis of gene

310 expression patterns through perturbation testing revealed trends ($P = 0.07$) in
311 expression across gene categories (**Fig. 5b**).

312 Interestingly, post-hoc analysis revealed that four phenotypic attributes
313 (syndromic features, mixed hearing loss, and hearing loss onset) were significantly
314 associated with pathogenic variants in the categories (**Figs. 5c-d and**
315 **Supplementary Table 7**). Causal genes more prevalent among patients with
316 syndromic features (i.e., *EYA1*, *SIX1*, and *MT-TL1*) were significantly enriched in
317 categories 6 and 7. These findings were in line with the cell type specificities of the
318 genes, since genes in categories 6 and 7 are more broadly expressed in multiple
319 organs and cell types (**Supplementary Fig. 6a**). Genes associated with mixed type
320 manifestation (i.e., *POU3F4*, *EYA1*, and *SIX1*) were more prevalent in category 7
321 compared to in category 1 ($P = 0.001$). We speculate that the genes associated with
322 transcriptional regulation may affect the development of the second branchial arch of
323 the middle ear, and the third window of the inner ear, accounting for conductive
324 components of hearing loss. Furthermore, genes associated with early identification
325 of hearing loss onset were more predominant in category 4 compared to in category
326 3 ($P=0.001$). It is likely that major genes in category 4 (i.e., *GJB2* and *SLC26A4*) or
327 their encoded proteins play a critical role during the embryonic stage of inner ear
328 development, whereas major genes in category 3 (i.e., *MPZL2* and *KCNQ4*) or their
329 encoded proteins act primarily in postnatal period. Collectively, these data support
330 the development of a comprehensive genotype-phenotype map of SNHL, and shed
331 light on insights of previously undefined genotype-phenotype correlations.

332 Discussion

333 Unlike previous cohort studies limited by the heterogeneous nature of
334 phenotypes^{33,34}, our present findings provide a robust estimate of diagnostic rates
335 through a stepwise genetic testing approach from single-gene analysis to WGS,
336 integrated with functional assays and bioinformatic analysis, in a relatively large
337 cohort of patients with a single phenotype of SNHL. Herein, we demonstrated an
338 additional diagnostic yield of 19.2% (23/120) through the systematic application of
339 WGS in previously undiagnosed SNHL patients who had undergone exome
340 sequencing and targeted assays. Specifically, even among undiagnosed SNHL
341 patients following an automated WGS pipeline (Step 3-1), we observed that the
342 frequency of genome-wide single pathogenic allele in known recessive deafness
343 genes was higher than in control cohorts. Based on these findings, we hypothesized
344 that this elevated frequency of single pathogenic alleles (43%) is less likely to be
345 incidental carrier variants and instead suggests the presence of a second,
346 undetected hit in the opposite allele. Consequently, through SpliceAI-based deep
347 intronic variants analysis (Step 3-2), we identified 3 meaningful deep intronic variants
348 among 100 patients, including three *USH2A* deep intronic variants confirmed to be
349 causative. These findings suggest the potential for further diagnosis of undiagnosed
350 cases through additional molecular diagnostic approaches, such as multi-omics and
351 methylation sequencing analyses, thereby accelerating the diagnostic process.
352 Supporting this, Lunke et al. have shown the potential of the integration of multi-omic
353 approaches into genomic testing, leading to additional diagnoses and changed
354 critical care management³⁵.

355 We identified the genetic causes of SNHL in 55.6% of our cohort families,
356 with WGS and SpliceAI-based deep intronic variants analysis increasing the overall

357 diagnostic yield by more than 5%. The improved diagnostic yield through WGS and
358 in-depth analysis has been made possible by screening regions that are challenging
359 to detect with conventional methods, primarily including deep intronic variants, small
360 SVs, copy-neutral inversions, and complex genomic rearrangements. Among the 23
361 families with additional diagnoses identified through WGS and in-depth analysis, 16
362 cases (69.6%) could be diagnosed through reanalysis of targeted sequencing data
363 and exome-based CNV algorithms. However, 7 (30.4%) of these cases required
364 genome sequencing for a definitive diagnosis. Our study further provides clinical
365 guidelines for selecting SNHL patients who are most likely to benefit from WGS.
366 WGS proved more effective for genetic completion in SNHL patients with early-onset
367 or syndromic features, regardless of audiological characteristics (e.g., severity and
368 configuration), with trio-based WGS providing higher diagnostic yield.

369 Genetic diagnosis of SNHL is helpful not only for understanding clinical
370 manifestations but also for planning treatment options. Genetic information could
371 serve as a guide to clinical phenotypes and their natural course, highlighting the
372 importance of WGS in identifying additional genetic causes in undiagnosed patients.
373 In detail, early identification of genetic causes may be necessary for detecting
374 preclinical symptoms (e.g., ns-SNHL mimics)³⁰, and for providing reproductive
375 counseling, including guidance on next-baby planning and options for
376 preimplantation genetic testing, even in cases of nonsyndromic hearing loss³⁶.
377 Although targeted agents based on genotype are not yet commonly established in
378 many human genetic disorders, there have been significant advances in
379 personalized targeted therapy in recent years, including in the field of genetic
380 hearing loss³⁷⁻⁴¹. For example, three presently identified genomic variants in the
381 deep intronic region of *USH2A* are targetable by splice-switching antisense

382 oligonucleotide therapy (ASOs), offering an opportunity to slow down or even halt
383 disease progression in these patients. According to a framework for individualized
384 splice-switching ASO therapy⁴², the *USH2A* deep intronic variants that induce
385 pseudoexon inclusion without disrupting cryptic splicing sites were highly amenable
386 to ASO splice modulation. Furthermore, in theory, a subset of SVs—such as the
387 *EYA1* paracentric inversion (SNUH 734) and *EYA1* complex genomic
388 rearrangements (SNUH 536) linked to haploinsufficiency detected in WGS—can be
389 corrected using CRISPR-based editing approaches, including Cas9 nuclease with
390 paired gRNAs, CRISPR activation, and prime editing strategy⁴³⁻⁴⁵. The present study
391 provides good examples of the potential of inner ear precision medicine for SNHL
392 treatment, with broadened therapeutic targets identified through WGS and in-depth
393 analysis.

394 Our comprehensive genomic investigation further refined the genotype-
395 phenotype landscape of SNHL, revealing gene signatures based on phenotypes.
396 The distribution of phenotype-based signature genes identified in this study largely
397 aligns with findings from exome-based SNHL cohort studies. While this genetic
398 information could support genetic diagnosis and provide a rationale for in-depth
399 analysis in the clinical setting, further studies with larger cohorts are essential to
400 establish more specific phenotype-genotype correlations that account for variant
401 effects (e.g., allelic hierarchy). Furthermore, we found that genotype-phenotype
402 correlations were also present at the level of the molecular pathways of the genes in
403 the inner ear. The inner ear molecular functions within distinct subcategories of
404 genetic hearing loss were found to correlate with the single-cell expression patterns
405 of identified deafness genes. This new framework of genetic hearing loss suggests
406 that genes within each functional class exhibit not only distinct inner ear molecular

407 functions but also relatively homogeneous spatial expression patterns in the cochlea.
408 Unlike traditional genotype-phenotype correlations, which are often limited by
409 specific ethnicities, genotypes, or phenotypes, the classification based on inner ear
410 molecular pathways expands beyond the current understanding of SNHL and
411 provides insights for predicting phenotypes associated with newly identified deafness
412 genes.

413 Collectively, our results provide evidence for the clinical utility of the
414 integrated diagnostic approaches, including WGS, in real-world SNHL practice to
415 fully recognize the genomic architectures and associated phenotypic attributes,
416 paving the way toward precision medicine to come.
417

418 **Methods**

419 **Study cohort**

420 In this study, we utilized a prospective research design and focused on
421 participants attending the Hereditary Hearing Loss Clinic within the
422 Otorhinolaryngology division of the Center for Rare Diseases, Seoul National
423 University Hospital, Korea, between March 2021 and February 2023 (**Fig. 1**).
424 Patients were not included if they were referred from other centers with confirmed
425 genetic diagnoses or diagnosed as conductive hearing loss. In total, our SNHL
426 cohort comprised 394 unrelated families and 750 individuals including probands,
427 who exhibited hearing loss with sensorineural components, and their family
428 members. The demographic data and clinical phenotypes were retrieved from the
429 electronic medical records. The onset of hearing loss was classified into three
430 distinct categories⁴⁶: early identification (i.e., congenital or prelingual deafness
431 identified through failed newborn hearing screening test), delay identification (i.e.,
432 pediatric-onset deafness occurring by age 18 that does not meet the criteria for early
433 identification, regardless of newborn hearing screening confirmation), and adult
434 identification (i.e., documented adult-onset hearing loss). The syndromic features of
435 the patients in the cohort were evaluated during their first outpatient clinic visit based
436 on their medical histories and/or features in their clinical manifestations. The
437 presence of associated medical conditions (e.g., syndromic hearing loss) was
438 determined using the Tenth Revision of the International Statistical Classification of
439 Diseases and Related Health Problems (ICD-10) codes. All procedures were
440 approved by the Institutional Review Board of Seoul National University Hospital (no.
441 IRB-H-0905-041-281 and IRB-H-2202-045-1298).

442

443 **Audiological evaluation**

444 Depending on the participant's age, the hearing thresholds for six different
445 octaves (0.25, 0.5, 1, 2, 4, and 8 kHz) were evaluated using pure-tone audiometry
446 (PTA)⁴⁷. For patients under 3 years of age or having neurodevelopmental delay,
447 auditory brainstem response threshold (ABRT) and auditory steady-state response
448 (ASSR) were used to gauge the thresholds at four-octave frequencies (0.5, 1, 2, and
449 4 kHz). The conductive components were evaluated using comprehensive tests,
450 including tympanic membrane examination, tympanometry (probe tones of 226 and
451 1000 Hz), and/or bone conduction ABRT, particularly in younger subjects. Auditory
452 profiles were retrieved—such as asymmetry, severity, configuration, and progression.
453 The mean hearing threshold was determined using an average of the thresholds at
454 0.5, 1, 2, and 4 kHz, and the degree of hearing loss was categorized as mild-to-
455 moderate (21-40 dB or ≤ 20 dB with high-frequency hearing loss), moderate-to-
456 severe (41-70 dB, and severe-to-profound (≥ 71 dB)⁴⁷. Audiogram configurations
457 were categorized into one of five subtypes: down-sloping (i.e., consistent downward
458 trend observed across 250, 500, 1000, 2000, and 4000 Hz frequencies, with an
459 average threshold at 250 and 500 Hz ≤ 40 dB), ski-sloping (i.e., thresholds at 250 Hz
460 are ≤ 25 dB, with a decrease of ≥ 40 dB between 250–1 kHz or 500–2 kHz, or a
461 decrease of ≥ 70 dB across 250–4 or 8 kHz), cookie-bite (i.e., U-shaped), up-sloping
462 (i.e., rising), and flat (i.e., audiograms that does not fit down-sloping, ski-slope,
463 cookie-bite, or up-sloping configurations)⁴⁸. Asymmetric hearing loss was defined as
464 severe-to-profound hearing loss in the poorer ear, with an average hearing threshold
465 >30 dB HL and <55 dB HL in the better ear. The presence of interaural asymmetry (a
466 difference in average between the poorer ear and the better ear of 15 to less than 30
467 dB, and a difference in average between the poorer ear and the better ear of 30 or

468 more than 30 dB) was also assessed⁴⁹. To analyze hearing loss progression, serial
469 audiograms were used to retrieve the hearing threshold at all frequencies. Hearing
470 loss progression was assessed in cases with two or more audiograms documented
471 during the follow-up period, with at least a one-year interval between documentation.
472 Cases with only one audiogram or follow-up duration of less than 1-year were
473 classified as not available (i.e., N/A). Profound SNHL with thresholds ≥ 90 dB at 500
474 Hz was classified as not determined (i.e., N/D). Hearing loss progression in this
475 study was categorized as substantial (≥ 10 dB deterioration at three or more
476 frequencies), mild (≥ 5 dB deterioration at three or more frequencies or ≥ 10 dB
477 deterioration at one or two frequencies), and none (if neither substantial nor mild
478 criteria were met).

479

480 **Real-time polymerase chain reaction and *GJB2* sequencing**

481 Genomic DNA was extracted from peripheral blood samples utilizing the
482 Chemagic 360 instrument (Perkin Elmer, Baesweiler, Germany). Real-time
483 polymerase chain reaction (PCR) was performed using the U-TOP™ HL Genotyping
484 Kit Ver1 and Ver2, along with a CFX96 Real-Time PCR Detection System (Bio-Rad,
485 Hercules, CA, USA)^{50,51}. This process was used to examine 22 pathogenic variants
486 across 10 deafness genes. The data collected from this procedure were analyzed
487 using Bio-Rad CFX manager v1.6 software. Variants were identified through the
488 fluorescence signals from the detection probes, which corresponded to the melting
489 temperature (T_m), as specified by the standard protocol in the manufacturer's
490 manual. We additionally conducted sequencing of the *GJB2* single gene, following a
491 previously described method⁵².

492

493 **Targeted panel sequencing and whole-exome sequencing**

494 We utilized TPS or WES to sequence the exonic regions of SNHL-related
495 genes. The target regions were captured using a SureSelect DNA targeted
496 sequencing panel for TPS, and a SureSelectXT Human All Exon V5 for WES (Agilent
497 Technologies, Santa Clara, CA, USA). A library was prepared following the
498 manufacturer's instructions, and was paired-end sequenced using a NovaSeq 6000
499 sequencing system (Illumina, San Diego, CA, USA).

500 Sequence reads were aligned to the human reference genome (GRCh38)
501 and processed according to the Genome Analysis Toolkit (GATK) best-practice
502 pipeline for calling single nucleotide variants (SNVs) and short insertions/deletions
503 (indels)⁵³. The ANNOVAR program was used for variant annotation, such as the
504 RefSeq gene set and Genome Aggregation Database (gnomAD)^{23,54}. Rare non-silent
505 variants were selected as candidates, including nonsynonymous SNVs, coding
506 indels, and splicing variants. We also used the Korean Reference Genome Database
507 (KRGDB) and KOVA databases for further filtration of ethnic-specific variants^{24,55}.
508 Additionally, the ClinVar and HGMD databases were screened to check whether
509 candidate variants had been previously identified in other patients^{56,57}.

510 We classified candidate variants according to the ACMG-AMP guidelines
511 using the InterVar program^{26,58}, and manually curated the classifications following the
512 modified guidelines for SNHL⁵⁹.

513

514 **Multiplex ligation-dependent probe amplification and mitochondria panel** 515 **sequencing**

516 For individuals displaying non-syndromic, symmetric, mild-to-moderate
517 SNHL, we evaluated copy number variations (CNVs) using the SALSA MLPA

518 Probemix P461-B1 *STRC-CATSPER2-OTOA* (MRC-Holland, Amsterdam,
519 Netherlands)²¹. Additionally, for patients showing evidence of EVA on temporal bone
520 CT and/or internal acoustic canal MRI and clinical features of BOR/BO syndrome,
521 we performed *SLC26A4* and *EYA1* MLPA tests, respectively, using the SALSA MLPA
522 Probemix P280-B4 *SLC26A4* and the SALSA MLPA Probemix P153-B2 *EYA1* (MRC-
523 Holland). We analyzed the amplification products using an ABI PRISM 3130 Genetic
524 Analyzer (Applied Biosystems, Foster City, CA, USA) and interpreted the results
525 using Gene Marker 1.91 software (SoftGenetics, State College, PA, USA).

526 For mitochondria panel sequencing, DNA was extracted from peripheral
527 blood samples using the Chemagic 360 instrument (Perkin Elmer, Baesweiler,
528 Germany). The complete human mitochondrial genome was amplified in two
529 overlapping fragments: fragment I (spanning 9,289 bp), and fragment II (spanning
530 7,626 bp). Fragment 1 was amplified using the primer pair hmtF1 569 (5'-
531 AACCAAACCCCAAAGACACC-3') and hmtR1 9819 (5'-
532 GCCAATAATGACGTGAAGTCC-3'), and fragment II was amplified using the primer
533 pair htmF2 9611 (5'-TCCCCTCCTAAACACATCC-3') and hmtR2 626 (5'-
534 TTTATGGGGTGATGTGAGCC-3')⁶⁰. PCR reactions were conducted using the
535 following cycling parameters: initial denaturation at 94 °C for 2 min; 10 cycles of
536 94 °C for 15 s, 65 °C for 30 s, and 68 °C for 5 min; 25 cycles of 94 °C for 15 s, 65 °C
537 for 30 s, and 68 °C for 5 min; and a final extension at 68 °C for 7 min. Subsequently,
538 a library was generated using the Nextera DNA Flex Library Prep Kit (Illumina)
539 following the manufacturer's instructions. Paired-end sequencing was performed with
540 the generation of 150-bp reads on the MiSeq platform (Illumina). Bioinformatic
541 processes, including alignment and annotation, were performed using NextGene
542 Version 2.4.0.1 (Softgenetics).

543

544 **Selection of the target population for whole-genome sequencing**

545 All patients with s-SNHL ($n = 21$) who remained undiagnosed after exome
546 sequencing and other techniques underwent WGS. Conversely, in patients with ns-
547 SNHL ($n = 177$) who remained undiagnosed, we determined the sample
548 representativeness for WGS. First, we estimated the sample size with a 7% margin
549 of error and a 95% CI. Second, we employed a probability sampling method,
550 specifically stratified sampling, considering a significant heterogeneity of SNHL
551 patients with respect to audiological characteristics. Relevant covariates, including
552 SNHL onset, severity, and asymmetry phenotypes, were used as criteria for
553 stratification. Thus, for the 177 undiagnosed ns-SNHL patients, a representative
554 validation was conducted, and WGS was ultimately performed on 99 families,
555 exceeding the required sample size of 94, which corresponds to a 7% margin of
556 error and a 95% CI. A representative sample was then obtained by randomly
557 sampling within each stratum. Chi-square tests were conducted to assess
558 differences across these strata. Overall, our methodology combines a well-thought-
559 out sample size estimation with a stratified sampling approach and proper statistical
560 validation, making it a robust approach for selecting a representative sample for
561 WGS in undiagnosed ns-SNHL patients.

562

563 **Library construction and automated analytic pipeline for whole-genome** 564 **sequencing**

565 To obtain genomic DNA, peripheral blood samples were collected from
566 probands with or without their parents. The entire process of genome sequencing,
567 analysis, and interpretation was performed using the RareVision™ system (Inocras,

568 San Diego, CA, USA). Genomic DNA was extracted from blood samples using the
569 Allprep DNA/RNA kits (Qiagen, Venlo, Netherlands). DNA libraries were prepared
570 using TruSeq DNA PCR-Free Library Prep Kits (Illumina) and sequenced on the
571 Illumina NovaSeq6000 platform with an average depth of coverage of 30x. The
572 obtained genome sequences were aligned to the human reference genome
573 (GRCh38) using the BWA-MEM algorithm. PCR duplicates were removed using
574 SAMBLASTER⁶¹. The initial mutation calling for base substitutions and short indels
575 was performed using HaplotypeCaller and Strelka2, respectively⁶². SVs were
576 identified using Delly. Variants were filtered, and their Mendelian inheritance patterns
577 were assessed. De novo mutations were detected, and their potential impacts were
578 predicted. The pathogenicity prediction was further enhanced by using in-house-
579 developed software that automatically integrates updated databases. The final
580 evaluation of variant pathogenicity was determined by medical geneticists,
581 considering the patient's phenotype and familial history.

582

583 **In vitro splicing analysis using minigene assay**

584 Fragments carrying the *USH2A* intron 37 reduced to 916 bp containing
585 c.7120+1475A or c.7120+1475A>G, and intron 64 reduced to 845 bp containing
586 c.14135-3169A or c.14135-3169A>G, were amplified and cloned into the pSPL3
587 vector, between the exon splice donor (SD) and splice acceptor (SA), using the
588 EcoRI and NdeI restriction sites. Human epithelial kidney 293T (HEK293T) cells
589 were seeded in a six-well culture plate and incubated at 37 °C in a 5% CO₂
590 atmosphere in Dulbecco's modified Eagle's medium (LM001-05; Welgene,
591 Gyeongsan, Korea) containing 10% fetal bovine serum (12483-020; Gibco, Carlsbad,
592 CA, USA), 100 units/mL penicillin/streptomycin (LS015-01; Welgene), and 2 mM L-

593 glutamine (LS002-01; Welgene). On the next day, the cells were transfected with 2
594 μg pSPL3 plasmid using Lipofectamine 3000 reagent (L3000001; Invitrogen,
595 Carlsbad, CA, USA), according to the manufacturer's guidelines. After 24 hours, the
596 cells were harvested, and the total RNA was extracted using TRIzol Reagent
597 (15596026; Invitrogen) and chloroform. From 1 μg RNA, cDNA was prepared by
598 reverse transcription using the Accupower RT-preMix (K-2041; Bioneer, Daejeon,
599 Korea). Splicing analysis was performed by PCR amplification with Taq DNA
600 Polymerase (E-2011-1; Bioneer) using the following vector-specific primers: SD6
601 (5'-TCTGAGTCACCTGGACAACC-3') and SA2 (5'-
602 ATCTCAGTGGTATTTGTGAGC-3').

603

604 **Fibroblast cell culture**

605 A skin biopsy was obtained from a donor under local anesthesia and
606 preserved in Phosphate Buffered Saline (PBS). The biopsy was divided into 9-12
607 distinct segments and seeded into a 12-well plate containing DMEM supplemented
608 with 20% FBS. Once the segments reached confluence, fibroblasts were harvested
609 for further expansion.

610

611 **Oxygen consumption rate**

612 Cellular OCR was measured in real-time using the Seahorse XF96
613 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA, USA) per the
614 manufacturer's protocol. Cells (8.0×10^3 fibroblasts) were seeded in 100 μL of
615 growth medium in Seahorse 96-well microplates and incubated at 37 °C with 5%
616 CO₂ for 24 hours. Prior to the assay, cells were washed with assay running media
617 (unbuffered DMEM supplemented with 25 mM glucose, 1 mM glutamine, and 1 mM

618 sodium pyruvate) and equilibrated in a non-CO₂ incubator overnight. Calibration of
619 the assay plate was performed overnight in a non-CO₂ incubator. Once calibrated,
620 the cell plate replaced the assay plate, and OCR was measured simultaneously. The
621 assay protocol involved sequential injection of four compounds to modulate
622 mitochondrial function and determine parameters such as basal respiration, maximal
623 respiration, and ATP production: oligomycin (1 μM), an ATP synthase inhibitor for
624 maximal glycolytic metabolism; carbonyl cyanide p-(trifluoromethoxy)
625 phenylhydrazone (FCCP) (1 μM), an ETC and OXPHOS uncoupler for peak oxygen
626 consumption and oxidative metabolism; rotenone and antimycin A (both at 1 μM),
627 inhibitors of ETC complexes I and III respectively, for non-mitochondrial respiration
628 assessment. The Seahorse analyzer recorded OCR values throughout the assay to
629 monitor cellular metabolic activity in real-time.

630

631 **Statistical analyses**

632 We used the Pearson chi-square test to identify variables that could
633 potentially differentiate between the genetically diagnosed and undiagnosed groups.
634 Following the computation of the OR and 95% CI for each value, we conducted a
635 logistic regression analysis, considering only the variables with *P* values of <0.05.
636 This approach facilitated the derivation of the adjusted OR. We also classified the 63
637 SNHL-associated genes that were identified during this study based on the
638 molecular mechanisms of inner-ear function. To verify the variance between groups
639 according to clinical phenotypes, we used the Pearson chi-square test. Finally, we
640 used Fisher's exact test based on the false discovery rate (FDR) to identify
641 statistically significant groups characterized by an adjusted *P* value of <0.05. In this
642 study, we define variables exhibiting *P* values of <0.05 as statistically significant.

643 Statistical analyses and visualizations were conducted using R Version 4.2.2, and
644 the corresponding code can be accessed at [https://github.com/SNUH-](https://github.com/SNUH-hEARgeneLab/WGS_analysis)
645 [hEARgeneLab/WGS analysis](https://github.com/SNUH-hEARgeneLab/WGS_analysis).

646

647 **Data availability:**

648 The data generated in this study are available in the Source Data file, which
649 is provided with this paper.

650

651 **References**

- 652 1 Lieu, J. E. C., Kenna, M., Anne, S. & Davidson, L. Hearing Loss in Children: A
653 Review. *JAMA* **324**, 2195-2205 (2020).
654 <https://doi.org/10.1001/jama.2020.17647>
- 655 2 Bowl, M. R. *et al.* A large scale hearing loss screen reveals an extensive
656 unexplored genetic landscape for auditory dysfunction. *Nature*
657 *communications* **8**, 886 (2017).
- 658 3 Pinero, J. *et al.* The DisGeNET knowledge platform for disease genomics:
659 2019 update. *Nucleic Acids Res* **48**, D845-D855 (2020).
660 <https://doi.org/10.1093/nar/gkz1021>
- 661 4 Martin, A. R. *et al.* PanelApp crowdsources expert knowledge to establish
662 consensus diagnostic gene panels. *Nat Genet* **51**, 1560-1565 (2019).
663 <https://doi.org/10.1038/s41588-019-0528-2>
- 664 5 Adams, D. R. & Eng, C. M. Next-Generation Sequencing to Diagnose
665 Suspected Genetic Disorders. *N Engl J Med* **379**, 1353-1362 (2018).
666 <https://doi.org/10.1056/NEJMra1711801>
- 667 6 Pajusalu, S. *et al.* Large gene panel sequencing in clinical diagnostics-results
668 from 501 consecutive cases. *Clin Genet* **93**, 78-83 (2018).
669 <https://doi.org/10.1111/cge.13031>
- 670 7 Aspromonte, M. C. *et al.* Characterization of intellectual disability and autism
671 comorbidity through gene panel sequencing. *Hum Mutat* **40**, 1346-1363
672 (2019). <https://doi.org/10.1002/humu.23822>
- 673 8 Liao, E. N., Taketa, E., Mohamad, N. I. & Chan, D. K. Outcomes of Gene
674 Panel Testing for Sensorineural Hearing Loss in a Diverse Patient Cohort.
675 *JAMA Netw Open* **5**, e2233441 (2022).
676 <https://doi.org/10.1001/jamanetworkopen.2022.33441>
- 677 9 Downie, L. *et al.* Exome sequencing in infants with congenital hearing
678 impairment: a population-based cohort study. *Eur J Hum Genet* **28**, 587-596
679 (2020). <https://doi.org/10.1038/s41431-019-0553-8>
- 680 10 Gu, X. *et al.* Genetic testing for sporadic hearing loss using targeted
681 massively parallel sequencing identifies 10 novel mutations. *Clin Genet* **87**,
682 588-593 (2015). <https://doi.org/10.1111/cge.12431>
- 683 11 Jung, J. *et al.* Genetic Predisposition to Sporadic Congenital Hearing Loss in

- 684 a Pediatric Population. *Sci Rep* **7**, 45973 (2017).
685 <https://doi.org/10.1038/srep45973>
- 686 12 Pennisi, E. Upstart DNA sequencers could be a “game changer.”. *Science* **376**,
687 1257-1258 (2022).
- 688 13 Retterer, K. *et al.* Clinical application of whole-exome sequencing across
689 clinical indications. *Genetics in Medicine* **18**, 696-704 (2016).
- 690 14 Wojcik, M. H. *et al.* Genome Sequencing for Diagnosing Rare Diseases. *N*
691 *Engl J Med* **390**, 1985-1997 (2024). <https://doi.org/10.1056/NEJMoa2314761>
- 692 15 Lee, S. *et al.* Whole genomic approach in mutation discovery of infantile
693 spasms patients. *Front Neurol* **13**, 944905 (2022).
694 <https://doi.org/10.3389/fneur.2022.944905>
- 695 16 Gallego-Martinez, A. *et al.* Using coding and non-coding rare variants to target
696 candidate genes in patients with severe tinnitus. *NPJ Genom Med* **7**, 70
697 (2022). <https://doi.org/10.1038/s41525-022-00341-w>
- 698 17 Huq, A. J. *et al.* Clinical impact of whole-genome sequencing in patients with
699 early-onset dementia. *J Neurol Neurosurg Psychiatry* (2022).
700 <https://doi.org/10.1136/jnnp-2021-328146>
- 701 18 Macken, W. L. *et al.* Specialist multidisciplinary input maximises rare disease
702 diagnoses from whole genome sequencing. *Nat Commun* **13**, 6324 (2022).
703 <https://doi.org/10.1038/s41467-022-32908-7>
- 704 19 van Eyk, C. L. *et al.* Yield of clinically reportable genetic variants in unselected
705 cerebral palsy by whole genome sequencing. *NPJ Genom Med* **6**, 74 (2021).
706 <https://doi.org/10.1038/s41525-021-00238-0>
- 707 20 Pagnamenta, A. T. *et al.* Structural and non-coding variants increase the
708 diagnostic yield of clinical whole genome sequencing for rare diseases.
709 *Genome Med* **15**, 94 (2023). <https://doi.org/10.1186/s13073-023-01240-0>
- 710 21 Kim, B. J. *et al.* Significant Mendelian genetic contribution to pediatric mild-to-
711 moderate hearing loss and its comprehensive diagnostic approach. *Genetics*
712 *in Medicine* **22**, 1119-1128 (2020).
- 713 22 Nam, D. W. *et al.* Molecular Genetic Etiology and Revisiting the Middle Ear
714 Surgery Outcomes of Branchio-Oto-Renal Syndrome: Experience in a Tertiary
715 Referral Center. *Otology & Neurotology* **44**, e319-e327 (2023).
- 716 23 Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from

- 717 variation in 141,456 humans. *Nature* **581**, 434-443 (2020).
718 <https://doi.org/10.1038/s41586-020-2308-7>
- 719 24 Lee, J. *et al.* A database of 5305 healthy Korean individuals reveals genetic
720 and clinical implications for an East Asian population. *Exp Mol Med* **54**, 1862-
721 1871 (2022). <https://doi.org/10.1038/s12276-022-00871-4>
- 722 25 Choi, W. H. *et al.* Functional pathogenicity of ESRRB variant of uncertain
723 significance contributes to hearing loss (DFNB35). *Sci Rep* **14**, 21215 (2024).
724 <https://doi.org/10.1038/s41598-024-70795-8>
- 725 26 Richards, S. *et al.* Standards and guidelines for the interpretation of sequence
726 variants: a joint consensus recommendation of the American College of
727 Medical Genetics and Genomics and the Association for Molecular Pathology.
728 *Genet Med* **17**, 405-424 (2015). <https://doi.org/10.1038/gim.2015.30>
- 729 27 Buchert, R. *et al.* SPATA5 mutations cause a distinct autosomal recessive
730 phenotype of intellectual disability, hypotonia and hearing loss. *Orphanet*
731 *Journal of Rare Diseases* **11**, 1-7 (2016).
- 732 28 Jaganathan, K. *et al.* Predicting Splicing from Primary Sequence with Deep
733 Learning. *Cell* **176**, 535-548 e524 (2019).
734 <https://doi.org/10.1016/j.cell.2018.12.015>
- 735 29 Yun, Y. *et al.* Expanding Genotype-Phenotype Correlation of CLCNKA and
736 CLCNKB Variants Linked to Hearing Loss. *Int J Mol Sci* **24** (2023).
737 <https://doi.org/10.3390/ijms242317077>
- 738 30 Nam, D. W. *et al.* Allelic hierarchy for USH2A influences auditory and visual
739 phenotypes in South Korean patients. *Sci Rep* **13**, 20239 (2023).
740 <https://doi.org/10.1038/s41598-023-47166-w>
- 741 31 Delmaghani, S. & El-Amraoui, A. Inner ear gene therapies take off: current
742 promises and future challenges. *Journal of clinical medicine* **9**, 2309 (2020).
- 743 32 van der Valk, W. H. *et al.* A single-cell level comparison of human inner ear
744 organoids with the human cochlea and vestibular organs. *Cell Rep* **42**,
745 112623 (2023). <https://doi.org/10.1016/j.celrep.2023.112623>
- 746 33 Investigators, G. P. P. *et al.* 100,000 Genomes Pilot on Rare-Disease
747 Diagnosis in Health Care - Preliminary Report. *N Engl J Med* **385**, 1868-1880
748 (2021). <https://doi.org/10.1056/NEJMoa2035790>
- 749 34 Turro, E. *et al.* Whole-genome sequencing of patients with rare diseases in a

- 750 national health system. *Nature* **583**, 96-102 (2020).
751 <https://doi.org/10.1038/s41586-020-2434-2>
- 752 35 Lunke, S. *et al.* Integrated multi-omics for rapid rare disease diagnosis on a
753 national scale. *Nat Med* **29**, 1681-1691 (2023).
754 <https://doi.org/10.1038/s41591-023-02401-9>
- 755 36 Yang, Y. *et al.* Reevaluating the splice-altering variant in TECTA as a cause of
756 nonsyndromic hearing loss DFNA8/12 by functional analysis of RNA. *Hum*
757 *Mol Genet* (2024). <https://doi.org/10.1093/hmg/ddae071>
- 758 37 Jiang, L., Wang, D., He, Y. & Shu, Y. Advances in gene therapy hold promise
759 for treating hereditary hearing loss. *Molecular Therapy* (2023).
- 760 38 Petit, C., Bonnet, C. & Safieddine, S. Deafness: from genetic architecture to
761 gene therapy. *Nature Reviews Genetics*, 1-22 (2023).
- 762 39 Yun, Y. & Lee, S. Y. Updates on Genetic Hearing Loss: From Diagnosis to
763 Targeted Therapies. *J Audiol Otol* **28**, 88-92 (2024).
764 <https://doi.org/10.7874/jao.2024.00157>
- 765 40 Lv, J. *et al.* AAV1-hOTOF gene therapy for autosomal recessive deafness 9: a
766 single-arm trial. *Lancet* **403**, 2317-2325 (2024). [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(23)02874-X)
767 [6736\(23\)02874-X](https://doi.org/10.1016/S0140-6736(23)02874-X)
- 768 41 Wang, H. *et al.* Bilateral gene therapy in children with autosomal recessive
769 deafness 9: single-arm trial results. *Nat Med* **30**, 1898-1904 (2024).
770 <https://doi.org/10.1038/s41591-024-03023-5>
- 771 42 Kim, J. *et al.* A framework for individualized splice-switching oligonucleotide
772 therapy. *Nature* **619**, 828-836 (2023). [https://doi.org/10.1038/s41586-023-](https://doi.org/10.1038/s41586-023-06277-0)
773 [06277-0](https://doi.org/10.1038/s41586-023-06277-0)
- 774 43 Kweon, J. *et al.* Targeted genomic translocations and inversions generated
775 using a paired prime editing strategy. *Molecular Therapy* **31**, 249-259 (2023).
- 776 44 Chen, P. J. & Liu, D. R. Prime editing for precise and highly versatile genome
777 manipulation. *Nature Reviews Genetics* **24**, 161-177 (2023).
- 778 45 Yi, H. *et al.* CRISPR-based editing strategies to rectify EYA1 complex
779 genomic rearrangement linked to haploinsufficiency. *Mol Ther Nucleic Acids*
780 **35**, 102199 (2024). <https://doi.org/10.1016/j.omtn.2024.102199>
- 781 46 Liao, E. N., Taketa, E., Mohamad, N. I. & Chan, D. K. Outcomes of Gene
782 Panel Testing for Sensorineural Hearing Loss in a Diverse Patient Cohort.

- 783 *JAMA Network Open* **5**, e2233441-e2233441 (2022).
- 784 47 Lee, S.-Y. *et al.* Natural course of residual hearing with reference to GJB2 and
785 SLC26A4 genotypes: Clinical implications for hearing rehabilitation. *Ear and*
786 *Hearing* **42**, 644-653 (2021).
- 787 48 Lee, S.-Y. *et al.* No auditory experience, no tinnitus: lessons from subjects
788 with congenital-and acquired single-sided deafness. *Hearing research* **354**, 9-
789 15 (2017).
- 790 49 Lin, P.-H. *et al.* Etiologic and audiologic characteristics of patients with
791 pediatric-onset unilateral and asymmetric sensorineural hearing loss. *JAMA*
792 *otolaryngology–head & neck surgery* **143**, 912-919 (2017).
- 793 50 Han, K.-H. *et al.* Establishment of a flexible real-time polymerase chain
794 reaction-based platform for detecting prevalent deafness mutations
795 associated with variable degree of sensorineural hearing loss in Koreans.
796 *PloS one* **11**, e0161756 (2016).
- 797 51 Lee, S.-Y. *et al.* Flexible real-time polymerase chain reaction-based platforms
798 for detecting deafness mutations in Koreans: A proposed guideline for the
799 etiologic diagnosis of auditory neuropathy spectrum disorder. *Diagnostics* **10**,
800 672 (2020).
- 801 52 Kim, S. Y. *et al.* Prevalence of p. V37I variant of GJB2 in mild or moderate
802 hearing loss in a pediatric population and the interpretation of its pathogenicity.
803 *PloS one* **8**, e61592 (2013).
- 804 53 Van der Auwera, G. A. *et al.* From FastQ data to high confidence variant calls:
805 the Genome Analysis Toolkit best practices pipeline. *Curr Protoc*
806 *Bioinformatics* **43**, 11 10 11-11 10 33 (2013).
807 <https://doi.org/10.1002/0471250953.bi1110s43>
- 808 54 Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of
809 genetic variants from high-throughput sequencing data. *Nucleic Acids Res* **38**,
810 e164 (2010). <https://doi.org/10.1093/nar/gkq603>
- 811 55 Jung, K. S. *et al.* KRGDB: the large-scale variant database of 1722 Koreans
812 based on whole genome sequencing. *Database (Oxford)* **2020** (2020).
813 <https://doi.org/10.1093/database/baaa030>
- 814 56 Stenson, P. D. *et al.* The Human Gene Mutation Database: towards a
815 comprehensive repository of inherited mutation data for medical research,

816 genetic diagnosis and next-generation sequencing studies. *Hum Genet* **136**,
817 665-677 (2017). <https://doi.org/10.1007/s00439-017-1779-6>

818 57 Landrum, M. J. *et al.* ClinVar: improving access to variant interpretations and
819 supporting evidence. *Nucleic Acids Res* **46**, D1062-D1067 (2018).
820 <https://doi.org/10.1093/nar/gkx1153>

821 58 Li, Q. & Wang, K. InterVar: Clinical Interpretation of Genetic Variants by the
822 2015 ACMG-AMP Guidelines. *Am J Hum Genet* **100**, 267-280 (2017).
823 <https://doi.org/10.1016/j.ajhg.2017.01.004>

824 59 Oza, A. M. *et al.* Expert specification of the ACMG/AMP variant interpretation
825 guidelines for genetic hearing loss. *Hum Mutat* **39**, 1593-1613 (2018).
826 <https://doi.org/10.1002/humu.23630>

827 60 Tang, S. & Huang, T. Characterization of mitochondrial DNA heteroplasmy
828 using a parallel sequencing system. *Biotechniques* **48**, 287-296 (2010).
829 <https://doi.org/10.2144/000113389>

830 61 Faust, G. G. & Hall, I. M. SAMBLASTER: fast duplicate marking and structural
831 variant read extraction. *Bioinformatics* **30**, 2503-2505 (2014).
832 <https://doi.org/10.1093/bioinformatics/btu314>

833 62 Kim, S. *et al.* Strelka2: fast and accurate calling of germline and somatic
834 variants. *Nat Methods* **15**, 591-594 (2018). [https://doi.org/10.1038/s41592-](https://doi.org/10.1038/s41592-018-0051-x)
835 [018-0051-x](https://doi.org/10.1038/s41592-018-0051-x)

836

837

838 **Acknowledgements:** This research was supported and funded by SNUH Kun-hee
839 Lee Child Cancer & Rare Disease Project, Republic of Korea (grant number: FP-
840 2022-00001-004 to Sang-Yeon Lee), SNU Medicine grant (basic and clinic
841 cooperation research grant number: 800-20230428 to Sang-Yeon Lee), and National
842 Research Foundation of Korea (NRF) and funded by the Ministry of Education (grant
843 number: 2022R1C1C1003147 to Sang-Yeon Lee). This research was supported by a
844 grant from the Korea Health Technology R&D Project through the Korea Health
845 Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare,
846 Republic of Korea (grant number: HI22C182600 to June-Young Koh).

847

848 **Contributions:** Concept and design: S.-Y.L., J.-H.C. Acquisition, analysis, or
849 interpretation of data: S.-Y.L., S.L., S.P., J.-Y.K., S.H.J., Y.J., W.H.C., J.H.C. Drafting
850 of the manuscript: S.-Y.L., S.L., S.P., J.-Y.K. Critical review of the manuscript for
851 important intellectual content: S.-Y.L., S.L., S.P., J.-Y.K. Statistical analysis: S.-Y.L.,
852 S.P., J.-Y.K. Obtained funding: S.-Y.L., J.-Y.K. Administrative, technical, or material
853 support: H.Y., S.L., M.-W.S., M.K.P., J.-J.S., B.Y.C., J.H.L. Supervision: J.-H.C. Y.S.J.

854

855 **Competing interests:**

856 Young Seok Ju is the founder of Inocras Inc., a genome analysis and interpretation
857 company. Young Seok Ju, June-Young Koh, Seongyeol Park, and Sangmoon Lee
858 hold stocks or stock options in Inocras Inc.

859 **Figure legends**

860 **Figure 1. Study design and diagnostic pipeline.** Flow diagram illustrating a
861 prospective, step-by-step genetic approach of 394 unrelated SNHL families and 750
862 individuals including probands in our cohort study. The diagnostic pipeline included
863 Step 1 (real-time PCR screening kit and direct *GJB2* sequencing), Step 2-1 (targeted
864 panel sequencing or whole-exome sequencing), Step 2-2 (MLPA and/or mtDNA
865 panel sequencing), Step 3-1 (whole-genome sequencing), and Step 3-2 (deep
866 intronic variant analysis). SNHL, sensorineural hearing loss; BOR/BO syndrome,
867 branchio-oto-renal/branchio-otic syndrome; MLPA, multiplex ligation-dependent
868 probe amplification; mtDNA, mitochondrial DNA; CI, confidence interval.

869

870 **Figure 2. Stepwise genetic diagnosis outcomes in SNHL patients.**

871 (a) Diagnostic yield of each genetic test for the whole SNHL cohort. Bar graph
872 showing the cumulative diagnostic rate according to genetic diagnosis steps. (b-c)
873 Diagnostic yield based on SNHL phenotypes and comparative analysis within the
874 whole SNHL cohort ($n = 394$ families; b) and within the WGS cases ($n = 120$ families;
875 c). Statistical significance for hearing loss onset and syndromic features was
876 determined using one-way ANOVA with Bonferroni's multiple comparisons tests and
877 the t-test, respectively. Significance levels are indicated as $*P < 0.05$. (d) Pearson's
878 correlation coefficient values for causative variants between the allele frequencies
879 (AFs) in our cohort and those from other populations. The AFs in our cohort showed
880 the highest correlation with the Korean database, KOVA, followed by the East Asian
881 population within gnomAD. (e) Dot plots shows the AF correlation between our
882 cohort and KOVA. There are three variants (pink dots) showing higher AFs in KOVA,
883 suggesting their phenotypic variability such as low penetrance or late onset

884 associated with these variants. A fitted line of linear regression model (blue line) and
885 95% confidence intervals (grey area) are displayed. (f) Distribution of variant
886 subtypes identified at each diagnostic step. WGS, whole-genome sequencing; MLPA,
887 multiplex ligation-dependent probe amplification; mtDNA, mitochondrial DNA; SNHL,
888 sensorineural hearing loss; SNV, single nucleotide variant; indel, insertion/deletion.
889

890 **Figure 3. Genomic landscape of the SNHL cohort.**

891 (a) Bar plot showing the frequencies and inheritance patterns of 63 SNHL-associated
892 genes from 219 genetically diagnosed families. Pie chart showing the percentages of
893 inheritance patterns. (b) Bar plot showing the mutational landscape of the total 352
894 likely pathogenic or pathogenic variants among the 63 SNHL genes. Pie chart
895 showing the percentages of variant types. (c) Proportion of novel variants among
896 identified causal variants. (d) Structural variants (SVs) were more common among
897 novel variants compared to previously reported variants. (e) Novel variants were
898 frequently identified through WGS (Step 3-1) and SpliceAI-based deep intronic
899 variants analysis (Step 3-2). (f, g) Schematic illustrations showing the location of
900 each identified pathogenic variant within *SPATA5* and *CLCNKA-CLCNKB* in the
901 probands (top, respectively). The genomic regions corresponding to each variant are
902 visualized using the integrative genomics viewer (bottom) for each figure. SNHL,
903 sensorineural hearing loss; SNV, single nucleotide variant; indel, insertion/deletion;
904 SV, structural variation.

905

906 **Figure 4. Analysis of carrier and deep intronic variants in undiagnosed SNHL** 907 **patients.**

908 (a) Schematic diagram illustrating carrier status identification and screening for

909 pathogenic deep intronic variants. (b) Bar plot showing the proportion of genetic
910 carriers for SNHL-related genes across each cohort. (c) Cumulative distribution plot
911 showing the MAF of candidate pathogenic variants across cohorts. (d) Schematic
912 illustration of the location of each identified pathogenic variant within *USH2A* in each
913 patient. (e) Schematic diagram of the pSPL3 vector with *USH2A* c.7120+1475A>G
914 (left), c.14134-3169A>G (middle), and c.4628-26037A>G (right). (f) Electrophoresis
915 gel image showing the bands corresponding to the pSPL3 empty vector (263 bp),
916 each variant, and wild-type. (g) Schematic representation of the splice products with
917 the wild-type splicing profile, and the splice variant profiles for each mutant type.
918 SNHL, sensory neural hearing loss; WGS, whole-genome sequencing; HC, healthy
919 control; AR, autosomal recessive; MOI, mode of inheritance; P, pathogenic; LP, likely
920 pathogenic; MAF, minor allele frequency; SV, structural variation; TE, transposable
921 element; SD, splicing donor; SA, splicing acceptor; PE, pseudoexon.


922

923 **Figure 5. Functional classification and clinical relevance of SNHL-related**
924 **genes.** (a) Schematic illustration of seven functional categories according to the
925 molecular mechanisms related to inner-ear function. (b) Heatmap showing the
926 correlation of gene expression patterns across different gene categories. (c)
927 Comparison of specific phenotypic presentations by seven inner ear functional
928 categories. The x-axis represents classifications based on inner ear molecular
929 functions, and y-axis indicates the proportion of clinical phenotypes among affected
930 probands. (d) Bar graphs showing post-hoc analysis using the false discovery rate.
931 Red represents the proportion of affected probands within the total number of
932 probands assigned to specific inner ear molecular functional groups.* denotes
933 statistical significance ($P < 0.05$).

Main figure 1


medRxiv preprint doi: <https://doi.org/10.1101/2024.12.08.24318682>; this version posted December 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY-NC-ND 4.0 International license](#).



Main figure 2


medRxiv preprint doi: <https://doi.org/10.1101/2024.12.08.24318682>; this version posted December 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-NC-ND 4.0 International license](#).



Main figure 3

medRxiv preprint doi: <https://doi.org/10.1101/2024.12.08.24318682>; this version posted December 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.


It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/)



Main figure 4

medRxiv preprint doi: <https://doi.org/10.1101/2024.12.08.24318682>; this version posted December 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



Main figure 5

medRxiv preprint doi: <https://doi.org/10.1101/2024.12.08.24318682>; this version posted December 10, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

